

Taiwan firm gets ANDA approval for generics of Pfizer's Procardia

09 April 2014 | News | By BioSpectrum Bureau



Singapore: Taiwan's TWi Pharmaceuticals has received ANDA approval of the generic equivalent to Procardia XL (Nifedipine) Extended Release Tablets, 30 mg, 60 mg and 90 mg, in the United States.

TWi has begun the launch preparation with its US distributor partner and will begin marketing the product as soon as the launch preparation is completed.

Procardia XL 30 mg, 60 mg and 90 mg, Extended Release Tablets marketed by Pfizer and the generic equivalent pharmaceuticals marketed by other companies, had annual combined sales of approximately USD116 million in the United States, according to IMS data as of December 2013.